Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 1

Status

Terminated 3Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Breast 1

Conditions

Neoplasm Metastasis 1Kidney Neoplasms 1Castrate-resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × dactolisib × Clear all
NCT01495247 2020-12-08

Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Novartis

Phase 1/2 Terminated
18 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01717898 2018-03-27

A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer

University of California, San Francisco

Phase 1/2 Terminated
6 enrolled 5 charts
Genitourinary

Castrate-resistant Prostate Cancer

NCT01453595 2016-02-29

BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Terminated
10 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡